The Lynx Group
Cholangiocarcinoma News

Emerging Therapies

March 2021, Vol 2, No 1 — April 13, 2021
In February 2021, Basilea Pharmaceuticals reported early results from the phase 2 FIDES-01 clinical trial (NCT03230318), which is evaluating the efficacy of derazantinib, an investigational small-molecule FGFR1-3 inhibitor, in patients with inoperable or advanced intrahepatic cholangiocarcinoma (CCA) and FGFR2 gene fusions or FGFR2 gene mutations or amplifications. Derazantinib also inhibits the colony-stimulating factor 1 receptor kinase (CSF1R). CSF1R-mediated signaling is important for the maintenance of tumor-promoting macrophages.
Read More

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: